Richard John Grant

AstraZeneca (United Kingdom)

Papers

1

Total Citations

58

H-Index

1

About

Richard John Grant is a pioneering figure in high-throughput screening technologies, with a primary focus on advancing the accuracy and efficiency of cell-based assays. His most influential work, "Achieving Accurate Compound Concentration in Cell-Based Screening: Validation of Acoustic Droplet Ejection Technology" (2009), has garnered 58 citations, establishing a foundational methodology for precise compound delivery in drug discovery. Grant’s major contribution lies in validating acoustic droplet ejection (ADE) as a reliable tool for minimizing solvent effects and ensuring consistent compound concentrations, directly addressing a critical bottleneck in early-stage pharmaceutical research. This work has been instrumental in streamlining screening workflows, reducing experimental variability, and enabling more robust hit identification. Beyond this landmark study, Grant’s broader research spans assay miniaturization, automation, and the integration of advanced liquid-handling techniques, with his findings widely adopted by academic and industrial labs. His achievements underscore a commitment to bridging engineering and biology, making him a key resource for students and researchers seeking to optimize screening platforms. Grant’s legacy is defined by practical, reproducible solutions that have accelerated the pace of drug discovery, cementing his role as a thought leader in assay development.

Research Focus

Key Achievements

1
H-Index
1
Papers
58
Total Citations
58
Avg Citations/Paper
🏆 Most Cited Paper
Achieving Accurate Compound Concentration in Cell-Based Screening: Validation of Acoustic Droplet Ejection Technology
58 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: AstraZeneca (United Kingdom)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago